Improving Outcomes for Women With Epithelial Ovarian Cancer

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing

DN Subramanian, M Zethoven, KI Pishas, ER Marinović, S McInerny, SM Rowley, PE Allan, L Devereux, D Cheasley, PA James, IG Campbell

2025-12-01

High-grade serous ovarian carcinoma (HGSOC) has a significant hereditary component, only half of which is explained. Previously, w..

Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes

LJ Collin, KL Cushing-Haugen, KL Terry, EL Goode, AH Wu, HR Harris, N Sasamoto, DW Cramer, F Modugno, E Elishaev, Z Fu, KB Moysich, PA Fasching, CL Pearce, U Menon, A Gentry-Maharaj, SA Gayther, N Wentzensen, MT Goodman, J George

2025-05-01

Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression pattern..

Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

NW Bateman, T Abulez, AR Soltis, A McPherson, S Choi, DW Garsed, A Pandey, C Tian, BL Hood, KA Conrads, PN Teng, J Oliver, G Gist, D Mitchell, TJ Litzi, CM Tarney, BA Crothers, P Mhawech-Fauceglia, CL Dalgard, MD Wilkerson

2024-12-01

We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade..

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

FAM Saner, K Takahashi, T Budden, A Pandey, D Ariyaratne, TA Zwimpfer, NS Meagher, S Fereday, L Twomey, KI Pishas, T Hoang, A Bolithon, N Traficante, K Alsop, EL Christie, EY Kang, GS Nelson, P Ghatage, CH Lee, MJ Riggan

2024-08-15

Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occu..

Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.

Flurina AM Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A Zwimpfer, Nicola S Meagher, Sian Fereday, Laura Twomey, Kathleen I Pishas, Therese Hoang, Adelyn Bolithon, Nadia Traficante, Kathryn Alsop, Elizabeth L Christie, Eun-Young Kang, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan

2023-11-10

BACKGROUND: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which ..

Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

O Pitiyarachchi, YC Lee, HW Sim, S Srirangan, C Mapagu, J Kirk, PR Harnett, RL Balleine, DDL Bowtell, G Samimi, AH Brand, DJ Marsh, P Beale, L Anderson, N Bouantoun, P Provan, SJ Ramus, A DeFazio, M Friedlander

2023-05-01

Background: Somatic pathogenic variants (PVs) in homologous recombination DNA repair (HR)-related genes found in high-grade serous..

CCNE1 Amplification as a Therapeutic Target

G Au-Yeung, L Mileshkin, DDL Bowtell

2023-03-20

Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

NL Burdett, MO Willis, K Alsop, AL Hunt, A Pandey, PT Hamilton, T Abulez, X Liu, T Hoang, S Craig, S Fereday, J Hendley, DW Garsed, K Milne, S Kalaria, A Marshall, BL Hood, KN Wilson, KA Conrads, KI Pishas

2023-03-01

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, wh..

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Ashley Weir, Eun-Young Kang, Nicola S Meagher, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S Anglesio, Matthias W Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H Brand, James D Brenton, Angela Brooks-Wilson

2023-01-26

Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (H..

Profiling the immune landscape in mucinous ovarian carcinoma

NS Meagher, P Hamilton, K Milne, S Thornton, B Harris, A Weir, J Alsop, C Bisinoto, JD Brenton, A Brooks-Wilson, DS Chiu, KL Cushing-Haugen, S Fereday, DW Garsed, SA Gayther, A Gentry-Maharaj, B Gilks, M Jimenez-Linan, CJ Kennedy, ND Le

2023-01-01

Objective: Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherap..

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

NS Meagher, KL Gorringe, M Wakefield, A Bolithon, CNI Pang, DS Chiu, MS Anglesio, KA Mallitt, JA Doherty, HR Harris, JM Schildkraut, A Berchuck, KL Cushing-Haugen, K Chezar, A Chou, A Tan, J Alsop, E Barlow, MW Beckmann, J Boros

2022-12-15

Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid ..

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

DW Garsed, A Pandey, S Fereday, CJ Kennedy, K Takahashi, K Alsop, PT Hamilton, J Hendley, YE Chiew, N Traficante, P Provan, D Ariyaratne, G Au-Yeung, NW Bateman, L Bowes, A Brand, EL Christie, JM Cunningham, M Friedlander, B Grout

2022-12-01

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after d..

TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

R Delahunty, L Nguyen, S Craig, B Creighton, D Ariyaratne, DW Garsed, E Christie, S Fereday, L Andrews, A Lewis, S Limb, A Pandey, J Hendley, N Traficante, N Carvajal, AB Spurdle, B Thompson, MT Parsons, V Beshay, M Volcheck

2022-06-20

PURPOSETubo-ovarian cancer (TOC) is a sentinel cancer for BRCA1 and BRCA2 pathogenic variants (PVs). Identification of a PV in the..

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival

KK Brieger, MT Phung, B Mukherjee, KM Bakulski, H Anton-Culver, EV Bandera, DDL Bowtell, DW Cramer, A DeFazio, JA Doherty, S Fereday, RT Fortner, A Gentry-Maharaj, EL Goode, MT Goodman, HR Harris, K Matsuo, U Menon, F Modugno, KB Moysich

2022-02-01

Background: There is suggestive evidence that inflammation is (IRRS) was developed, and its association with survival was related ..

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

A Nath, PA Cosgrove, H Mirsafian, EL Christie, L Pflieger, B Copeland, S Majumdar, MC Cristea, ES Han, SJ Lee, EW Wang, S Fereday, N Traficante, R Salgia, T Werner, AL Cohen, P Moos, JT Chang, DDL Bowtell, AH Bild

2021-12-01

The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.

Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild

2021-07-01

<jats:title>Abstract</jats:title> <jats:p>The evolution of resistance in high-grade serous ovarian cancer (HGSOC) c..

Oncologists’ perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer

P Hemming, R Kaur, B Meiser, J McKinley, MA Young, PA James, LE Forrest

2021-07-01

Poly ADP ribose polymerase (PARP) inhibitors offer a survival advantage to women with high-grade serous ovarian cancer who have a ..

Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

D Cheasley, A Nigam, M Zethoven, S Hunter, D Etemadmoghadam, T Semple, P Allan, MS Carey, ML Fernandez, A Dawson, M Köbel, DG Huntsman, C Le Page, AM Mes-Masson, D Provencher, N Hacker, Y Gao, D Bowtell, A deFazio, KL Gorringe

2021-01-01

Low-grade serous ovarian carcinoma (LGSOC) is associated with a poor response to existing chemotherapy, highlighting the need to p..

Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes

DN Subramanian, M Zethoven, S McInerny, JA Morgan, SM Rowley, JEA Lee, N Li, KL Gorringe, PA James, IG Campbell

2020-12-01

High-grade serous ovarian carcinoma (HGSOC) has a significant hereditary component, approximately half of which cannot be explaine..

The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients

M Gleeson, M Kentwell, B Meiser, J Do, S Nevin, N Taylor, K Barlow-Stewart, J Kirk, P James, CL Scott, R Williams, K Gamet, J Burke, M Murphy, YC Antill, A Pearn, N Pachter, C Ebzery, N Poplawski, M Friedlander

2020-08-01

Background: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making traditional coordination of gen..

Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer

E Tutty, L Petelin, J McKinley, MA Young, B Meiser, VM Rasmussen, R Forbes Shepherd, PA James, LE Forrest

2019-08-01

Systemic healthcare issues and geographical challenges restrict women’s access to BRCA1/2 testing to inform the use of tailored tr..

Going to extremes: determinants of extraordinary response and survival in patients with cancer

FAM Saner, A Herschtal, BH Nelson, A deFazio, EL Goode, SJ Ramus, A Pandey, JA Beach, S Fereday, A Berchuck, S Lheureux, CL Pearce, PD Pharoah, MC Pike, DW Garsed, DDL Bowtell

2019-06-01

Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the m..

Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility

SM Rowley, L Mascarenhas, L Devereux, N Li, KC Amarasinghe, M Zethoven, JEA Lee, A Lewis, JA Morgan, S Limb, MA Young, PA James, AH Trainer, IG Campbell

2019-04-01

Purpose: The identification of carriers of hereditary breast and ovarian cancer (HBOC) gene variants through family cancer history..

Survival following chemotherapy in ovarian clear cell carcinoma is not associated with pathological misclassification of tumor histotype

M Takenaka, M Köbel, DW Garsed, S Fereday, A Pandey, D Etemadmoghadam, J Hendley, A Kawabata, D Noguchi, N Yanaihara, H Takahashi, T Kiyokawa, M Ikegami, H Takano, S Isonishi, K Ochiai, S Gadipally, T Semple, D Vassiliadis, K Amarasinghe

2019-01-01

Purpose: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcom..

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

D Aziz, D Etemadmoghadam, CE Caldon, G Au-Yeung, N Deng, R Hutchinson, D Bowtell, P Waring

2018-11-01

Objectives: Readily apparent cyclin E1 expression occurs in 50% of HGSOC, but only half are linked to 19q12 locus amplification. T..

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

M Friedlander, U Matulonis, C Gourley, A du Bois, I Vergote, G Rustin, C Scott, W Meier, R Shapira-Frommer, T Safra, D Matei, V Shirinkin, F Selle, A Fielding, ES Lowe, EL McMurtry, S Spencer, P Rowe, H Mann, D Parry

2018-10-30

Background: In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in pat..

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

PF Rambau, RA Vierkant, MP Intermaggio, LE Kelemen, MT Goodman, E Herpel, PD Pharoah, S Kommoss, M Jimenez-Linan, BY Karlan, A Gentry-Maharaj, U Menon, SH Polo, FJ Candido Dos Reis, JA Doherty, SA Gayther, R Sharma, MC Larson, PR Harnett, E Hatfield

2018-10-01

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it..